SCI时时刷

search
+
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
Synergistic effect of adavosertib and fimepinostat on acute myeloid leukemia cells by enhancing the induction of DNA damage
In recent years, a number of novel pharmaceutical agents have received approval for the management of acute myeloid leukem...
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects
Venadaparib is a next-generation poly(ADP-ribose) polymerase inhibitor under development for treating gastric cancer. This...
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
Targeted delivery of liposomal Ribociclib to SLC7A5 transporters in breast cancer cells
This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, As...
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
A bispecific antibody targeting HER2 and CLDN18.2 eliminates gastric cancer cells expressing dual antigens by enhancing the immune effector function
Gastric cancer (GC) is widely regarded as one of the toughest cancers to treat. Trastuzumab, which targets the human epide...
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis
Nivolumab can cause fatal myocarditis. We aimed to analyze the clinical characteristics of nivolumab-induced myocarditis a...
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Navitoclax (ABT-263) is an oral BCL2 homology-3 mimetic that binds with high affinity to pro-survival BCL2 proteins, resul...
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer
Part E of the KEYNOTE-011 (NCT01840579) study assessed the safety and antitumor activity of pembrolizumab plus platinum-et...
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
C-X-C motif chemokine receptor 2 (CXCR2) has a role in tumor progression, lineage plasticity, and reduction of immune chec...
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
RPTOR mutation: a novel predictor of efficacious immunotherapy in melanoma
Identifying biomarkers to evaluate the therapeutic effect of immune checkpoint inhibitors (ICIs) is crucial. Regulatory As...
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Clinical characteristics, diagnosis, treatment, and prognosis of nivolumab induced gastritis
Gastritis has recently been reported to be associated with nivolumab, and the clinical characteristics of nivolumab induce...
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-
Dexamethasone is one of the key antiemetic agents and is widely used even now. However, dexamethasone has been associated ...
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma
Indoleamine-2,3-dioxygenase (IDO) helps orchestrate immune suppression and checkpoint inhibitor resistance in hepatocellul...
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
Molecular profiling and prognostic analysis in Chinese cholangiocarcinoma: an observational, retrospective single-center study
Cholangiocarcinoma (CCA) is a primary malignancy which is often diagnosed when it is advanced and inoperable due to the la...
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
Immunoneoadjuvant therapy with immune checkpoint inhibitors of gastric cancer: an emerging exemplification
Advances in immune checkpoint inhibitors (ICIs) have enabled more effective treatment for individuals with various types o...
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis
Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis
Hemophagocytic lymphohistiocytosis (HLH) is a rare and fatal adverse reaction to pembrolizumab. The clinical characteristi...
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer
Clinical characteristics and prognostic impact of immune checkpoint inhibitor-associated myocarditis in advanced non-small cell lung cancer
Myocarditis is a rare immune-related adverse events (irAEs) with high mortality rates, with few reports on its clinical ch...
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
Alterations in the DNA damage response play a crucial role in radio- and chemoresistance of neoplastic cells. Activation o...
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide
Endosomal recycling inhibitors downregulate the androgen receptor and synergise with enzalutamide
Prostate cancer is the second most frequent cancer diagnosed in men, and accounts for one-fifth of cancer associated death...
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1–3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial
Pemigatinib is a selective fibroblast growth factor receptor (FGFR)1–3 inhibitor and has demonstrated acceptable tol...
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells
Antitumor activity of the new tyrphostin briva against BRAFV600E-mutant colorectal carcinoma cells
Because of a reduced sensitivity of BRAF-mutant colorectal cancers to BRAF inhibitor treatment when compared with BRAF-mut...
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
Optimal first-line treatment strategies of systemic therapy for unresectable gastrointestinal neuroendocrine tumors based on the opinions of Japanese experts.
There are several options for systemic therapy of gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN), including som...
Gastrointestinal signet ring cell malignancy: current advancement and future prospects
Gastrointestinal signet ring cell malignancy: current advancement and future prospects
Globally, gastrointestinal cancer is the most widespread neoplastic disease and the primary contributor to cancer-associat...
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Therapeutic effectiveness of anlotinib combined with etoposide in extensive-stage small-cell lung cancer: a single-arm, phase II trial
Anlotinib plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC) achieves good eff...
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation
Pulmonary enteric adenocarcinoma (PEAC) is a rare lung adenocarcinoma with morphological and immunohistochemical similarit...
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States
This open-label, phase 1/1b study was conducted to evaluate the safety, tolerability, and pharmacokinetics (PK) of fruquin...
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid
Clinical characterization, treatment, and outcome of nivolumab-induced bullous pemphigoid
Bullous pemphigoid (BP) is a serious and rare complication of nivolumab. This study aimed to explore the clinical characte...
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
The intravenous administration (IV) of daratumumab sometimes causes an infusion reaction and needs a long infusion time. R...
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia
A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia
Approximately 60%–80% of patients who achieve complete remission eventually relapse after conventional chemotherapy ...
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer
A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer
Previously, we generated a novel bispecific antibody (BsAb) simultaneously targeting both c-MET and PD-1 (PDCD1), which ca...
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab
Early on-treatment C-reactive protein and its kinetics predict survival and response in recurrent and/or metastatic head and neck cancer patients receiving first-line pembrolizumab
Purpose: First-line immune checkpoint blockade has improved the prognosis of recurrent and/or metastatic head and neck squ...
阅读更多
format_indent_increase